Unlock instant, AI-driven research and patent intelligence for your innovation.

P-oxycyclohexanone and l-phenylalanine mustard copolymer and its application

A technology of phenylalanine nitrogen mustard and copolymer, which is applied in the direction of drug combination, drug delivery, medical preparations of non-active ingredients, etc., can solve the problems of high drug toxicity and side effects, and achieve the effect of inhibiting proliferation

Active Publication Date: 2019-05-17
川北医学院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of them are oral preparations, and its hydrochloride can be injected intravenously, but the drug is highly toxic, and the above systemic administration methods are likely to cause a variety of toxic and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • P-oxycyclohexanone and l-phenylalanine mustard copolymer and its application
  • P-oxycyclohexanone and l-phenylalanine mustard copolymer and its application
  • P-oxycyclohexanone and l-phenylalanine mustard copolymer and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Preparation and Characterization of PDCM Polymer

[0032] 1) Preparation of PDCM polymer

[0033] 4 g (13 mmol) of L-phenylalanine mustard and 3 g (10 mmol) of trimeric phosgene were placed in a round-bottomed flask, and after the air in the bottle was replaced with high-purity nitrogen, 50 mL of anhydrous tetrahydrofuran was added and refluxed for 3 hours. The solvent in the reaction solution was removed by rotary evaporation to obtain a yellow oil, which was the crude product of L-melphalan-N-carboxylic anhydride. The crude product was recrystallized three times from anhydrous tetrahydrofuran-n-hexane. Pure L-melphalan-N-carboxylic anhydride was obtained. 1 H NMR (400MHz, DMSO-d 6 , 9.13, s, 1H, NHCO; 7.01, d, J=8Hz, 2H, phenyl H; 6.68, d, J=8Hz, 2H, phenyl H; 4.71, t, J=4Hz, 1H, CONHCHCO; 3.71, br , 8H, NCH 2 CH 2 Cl; 2.90, d, J=4Hz, 2H, CH 2 -phenyl.), yield 57%.

[0034] L-phenylalanine mustard-N-carboxylic anhydride 2.47g (7.4mmol), p-oxycyclohexanone 5g (...

Embodiment 2

[0043] Covalently Bonded Chemotherapeutic Drug L-Phenylalanine Mustard Sustained Release Nanoparticles

[0044] PDCM-1, PDCM-2, and PDCM-3 were prepared into their corresponding nanoparticles by electrostatic spraying method. Take PDCM-3 as an example: Dissolve PDCM-3 in a mixed solvent of hexafluoroisopropanol / methanol (9:1, v / v) to prepare a solution with a concentration of 5% w / v, and add DTBA at 2mmol / Add the concentration of L into the solution, place the solution in a syringe whose needle tip is connected to an 8KV high-voltage DC power supply, place the syringe on a continuous micro-injection pump, the injection rate is 0.2mL / h, and place 75vol.% ethanol aqueous solution 10cm below the needle tip as the negative electrode The receiving device is connected to -2.5KV high voltage DC power supply. Under the action of electrostatic force, the polymer droplet cracks, dries, and shrinks to receive PDCM-3 nanoparticles in the receiving liquid. The size of the prepared PDCM ...

Embodiment 3

[0046] Inhibitory Effect of PDCM Nanoparticles on Cancer Cell Proliferation

[0047] Different concentrations of PDCM-2 nanoparticles were placed in the cell culture medium of U-87 (human glioma cell line), MCF-7 (human breast cancer cell line), and SKOV-3 (human ovarian cancer cell line) as Experimental groups 1, 2, and 3; normal culture medium was used in the control group, and the specific groups are shown in Table 2 below. The control group and the experimental group were incubated at room temperature for corresponding time.

[0048] Table 2. Test components of PDCM nanoparticles on cancer cell proliferation

[0049]

[0050] By comparing the OD value of the experimental group with the OD value of the control group, the inhibition rate of cell proliferation in the experimental group was obtained (such as figure 2 shown):

[0051] Proliferation inhibition rate={1-(OD value of experimental group / OD value of control group)}×100%

[0052] Depend on figure 2 It can be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
molecular weightaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a dioxanone and L-melphalan copolymer expressed in a structural formula (I) and an application of the dioxanone and L-melphalan copolymer in preparation of medicine for treating tumour. The invention also relates to a preparation method of the copolymer, a pharmaceutical composition by taking the copolymer as an active component, and a purpose of the pharmaceutical composition for treating tumor.

Description

technical field [0001] The invention relates to an L-phenylalanine system copolymer, in particular to a p-oxycyclohexanone and L-phenylalanine mustard copolymer and application thereof. Background technique [0002] In the current clinical practice, drug sustained-release carriers have been widely used in the field of tumor chemotherapy. The use of drug sustained-release carriers can enhance drug efficacy, reduce side effects and relieve patients' pain of multiple medications. Currently, the slow-release carriers of chemotherapy drugs used in clinical practice are mostly micro-nano microspheres or fibers wrapped in natural or synthetic polymer materials. Endocytosis enters the interior of the cell to further enhance the efficacy of the drug. However, most of the loading methods of carriers currently used in clinical practice are physical packaging, which has problems such as uneven release rate and low drug loading efficiency. Therefore, a drug release system with uniform ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C08G69/44C08G69/42A61K47/59A61K31/198A61K9/51A61P35/00B82Y30/00B82Y40/00
CPCA61K9/0002A61K9/5146A61K31/198B82Y30/00B82Y40/00C08G69/42C08G69/44
Inventor 王冰陈钏罗乐沈成义朱江吴昌强朱阳慧廖思维丁锐叶文萍张小明
Owner 川北医学院